AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Vascular endothelial growth factor receptor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P17948

UPID:

VGFR1_HUMAN

Alternative names:

Fms-like tyrosine kinase 1; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; Vascular permeability factor receptor

Alternative UPACC:

P17948; A3E342; A3E344; A8KA71; B0LPF1; B2BF46; B2BF47; B2BF48; B3FR89; B5A923; F5H5L6; O60722; P16057; Q12954

Background:

Vascular endothelial growth factor receptor 1 (VEGFR-1), also known as Fms-like tyrosine kinase 1, plays a pivotal role in angiogenesis, cell survival, and migration. It acts as a cell-surface receptor for VEGFA, VEGFB, and PGF, crucial for embryonic vasculature development and postnatal retinal vessel regression. VEGFR-1 has a unique function in regulating angiogenesis by modulating endothelial cell proliferation and forming heterodimers with KDR, influencing various signaling pathways including PLCG, MAPK, and AKT1.

Therapeutic significance:

Understanding the role of Vascular endothelial growth factor receptor 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.